The largest drug
discovery company
in the CEE region

More

Your integrated drug
discovery partner of choice

More

Developing breakthrough
therapies in oncology

More

Delivering comprehensive
research solutions to biotech
and pharma

More

News See all

Selvita and Sandoz chemists published in Bioorganic & Medicinal…

Krakow, Poland – 08 May 2018 – Selvita and Sandoz researchers have recently jointly published an article: “A short synthesis...
More

Institute of Hematology and Transfusion Medicine and Selvita publish…

Krakow, Poland - 26 April 2018 - Institute of Hematology and Transfusion Medicine, the leading Polish hematology and blood transfusion...
More

Selvita participates in BioTrinity 2018

Kraków, Poland – 23 April 2018 – Selvita will participate in the 2018 edition of BioTrinity conference, taking place in...
More

Selvita publishes research results on SEL24 in Oncotarget

Krakow, Poland – 16 April 2018 - Selvita, a clinical stage drug discovery and development company focused on innovative medicines...
More

Selvita to present new data from its oncology programs…

Kraków, Poland, 06 April 2018 – Selvita (WSE:SLV), a clinical stage drug discovery and development company focused on innovative medicines...
More

About Selvita

Selvita has two primary focus areas:

– to serve the drug discovery market as a customer centric provider of high quality, integrated drug discovery services and

– as a drug discovery company engaged in the research and development of breakthrough therapies in oncology.

More

Drug Discovery Services

Selvita is a global integrated drug discovery partner for the pharmaceutical and biotechnology industries.

We offer drug discovery support at every stage of the early discovery phase up to the preclinical research phase.

More

Research and Development

In its internal research and development efforts, Selvita focuses on different dimensions of oncology.


The company’s most advanced R&D program is SEL24, a dual PIM/FLT3 kinase inhibitor currently in Phase I/II clinical study, in acute myeloid leukemia.

More

Investor Relations SLV +0,00PLN +1,63%

Share price 2018-05-24 17:04:35

56,00 PLN More

Careers

We are a multicultural and a multinational company employing professionals from all over the world.

Find out who we’re courrently looking for and what we can offer our employees.

More